FGF19 and metabolic dysfunction-associated steatotic liver disease: Exogenous administration of FGF19 and its analog NGM282 did not correct hyperglycemia in diabetic patients, but caused a rapid and sustained reduction in hepatic Cyp7a1 levels and liver fat content in NAFLD patients22.